Melanoma from darkness to promise

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 34, Issue 2, 2011, Pages 179-187

  Blesa, Joan Manel Gasent ^a   Pulido, Enrique Grande ^b   Candel, Vicente Alberola ^c   Pulla, Mariano Provencio ^d  

^a Hospital de Denia   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

^c HOSPITAL ARNAU DE VILANOVA   (Spain)

^d HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

Angiogenesis; Melanoma; Targeted; Treatment

Indexed keywords

ALBINTERFERON ALPHA2B; ALPHA INTERFERON; AMIFOSTINE; AXITINIB; BEVACIZUMAB; CARBOPLATIN; CARMUSTINE; CISPLATIN; DACARBAZINE; ELESCLOMOL; ETARACIZUMAB; FOTEMUSTINE; IMATINIB; INTERLEUKIN 2; IPILIMUMAB; LOMEGUATRIB; NITROSOUREA; OBLIMERSEN; OXALIPLATIN; PACLITAXEL; PI 88; PLACEBO; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; SORAFENIB; TAMOXIFEN; TEMOZOLOMIDE; THALIDOMIDE; UNINDEXED DRUG; VINBLASTINE; VINCA ALKALOID;

ADD ON THERAPY; ADOPTIVE TRANSFER; ANEMIA; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; BRAIN METASTASIS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; DEEP VEIN THROMBOSIS; DIARRHEA; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; IMMUNE RESPONSE; LEUKOPENIA; LIVER CANCER; LIVER METASTASIS; LOW DRUG DOSE; MELANOMA; META ANALYSIS (TOPIC); METASTASIS; MONOTHERAPY; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SOLID TUMOR; T LYMPHOCYTE; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT RESPONSE; UVEA MELANOMA;

ADOPTIVE TRANSFER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; IMMUNOTHERAPY; MELANOMA; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; SIROLIMUS; SKIN NEOPLASMS;

EID: 79955957383     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3181d6b427     Document Type: Review

References (96)

1. Coates AS, Segelov E. Long term response to chemotherapy in patients with visceral metastatic melanoma. Ann Oncol. 1994;5:249-251. (Pubitemid 24097520)
2. Balch CM, Reintgen DS, Kirkwood JM, et al. Cutaneous melanoma. In: DeVita VT Jr, Hellman S, Rosenber SA, eds. Cancer: Principles and Practice of Oncology. 5th ed. Philadelphia, PA: Lippincott-Raven; 1997:1947-1994.
3. Falkson CI, Ibrahim J, Kirkwood JM, et al. Phase III trial of dacarbazine versus dacarbazine with interferon alfa-2b versus tamoxifen versus dacarbazine with interferon alfa-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol. 1998;16:1743-1751.
4. Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000;18:158-166. (Pubitemid 30036349)
5. Avril MF, Aamdal S, Grob JJ, et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol. 2004;22:1118-1125. (Pubitemid 41095046)
6. Eggermont AM, Kirkwood JM. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur J Cancer. 2004;40:1825-1836. (Pubitemid 39036756)
7. Bafaloukos D, Aravantinos G, Fountzilas G, et al. Docetaxel in combination with dacarbazine in patients with advanced melanoma. Oncology. 2002;63: 333-337. (Pubitemid 36151525)
8. Newlands ES, Blackledge GR, Slack JA, et al. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer. 1992;65:287-291.
9. Lee SM, Thatcher N, Margison GP. O6-alkylguanine-DNA alkyltrasferase depletion and regeneration in human peripheral lymphocytes following dacarbazine and fotemustine. Cancer Res. 1991;51:619-623.
10. Tawbi H, Tarhini A, Moschos S, et al. Phase I trial of lomeguatrib (PN) combined with dacarbazine (DTIC) for treatment of patients with melanoma and other solid tumors: initial results (2006 ASCO Annual Meeting Proceedings). J Clin Oncol. 2006;24(suppl):18S. Abstract 8016.
11. Plummer R, Lorigan P, Evans J, et al. First and flnal report of a phase II study of the poly-(ADP-ribosed) polymerase (PARR) inhibitor, AGO14699 in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM) (2006 ASCO Annual Meeting Proceedings). J Clin Oncol. 2006;24(suppl):18S. Abstract 8013.
12. Boaziz C, Breau JL, Morere JF, et al. Brain metastases of malignant melanomas. Bull Cancer. 1991;78:347-353.
13. Jacquillat C, Khayat D, Banzer P, et al. Final report of the French multicentric phase II study of the nitrosurea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer. 1990;66:1873-1878. (Pubitemid 20385954)
14. Calabresi E, Aapro M, Becquart D, et al. Multicenter phase II trial of the single fotemustine in patients with advanced malignant melanoma. Ann Oncol. 1991;2:377-378.
15. Kleeberg UR, Engel E, Israels P, et al. Palliative therapy of melanoma patients with fotemustine. Inverse relationship between tumor load and treatment effectiveness. A multicenter phase II trial of the EORTC-Mela-noma Cooperative Group (MCG). Melanoma Res. 1995;5:195-200.
16. Kirkwood JM, Agarwala S. Systemic cytotoxic and biologic therapy mela-noma. In: DeVita VT, Hellman S, Rosenberg SA, eds. PPO Updates. Vol 7. Philadelphia, PA: Lippincott; 1993:1
17. Glover D, Glick JH, Weiler C, et al. WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma. J Clin Oncol. 1987;5:574-578. (Pubitemid 17062494)
18. Glover D, Ibrahim J, Kirkwood J, et al. Phase II randomized trial of cisplatin and WR-2721 versus cisplatin alone for metastatic melanoma: an Eastern Cooperative Oncology Group Study (E1686). Melanoma Res. 2003;13:619-626. (Pubitemid 38296900)
19. Evans LM, Casper ES, Rosenbluth R. Participating community oncology program investigators: phase II trial of carboplatin in advanced malignant melanoma. Cancer Treat Rep. 1987;71:171-172. (Pubitemid 17030148)
20. Mohammed MQ, Retsas S. Oxaliplatin is active in vitro against human melanoma cell lines: comparison with cisplatin and carboplatin. Anticancer Drugs. 2000;11:859-863.
21. Lutzky J, Nunez Y, Graham P. A phase II trial of oxaliplatin in patients with advanced melanoma. 2006 ASCO Annual Meeting Proceedings (Post-meeting Edition). J Clin Oncol. 2006;24(suppl):18S. Abstract 18016.
22. Quagliana JM, Stephens RL, Baker LH, et al. Vindesine in patients with metastatic malignant melanoma. A Southwest Oncology Group study. J Clin Oncol. 1984;4:316-319. (Pubitemid 14106999)
23. Einzig AI, Hochester H, Wiernik PH, et al. A phase II study of Taxol in patients with malignant melanoma. Invest New Drugs. 1991;9:59-64.
24. Bedikian AY, Weiss GR, Legha SS, et al. Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy. J Clin Oncol. 1995;13:2859-2899.
25. Aamdal S, Wolff I, Kaplan S, et al. Docetaxel (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC Early Clinical Trials Group. Eur J Cancer. 1994;30A:1061-1064.
26. Hersh E, O'Day S, Gonzalez R, et al. Phase II trial of ABI-007 (Abraxane) in previously treated and chemotherapy-naive patients with metastatic melanoma. Melanoma Res. 2006;16:S78. Abstract ABS-0141.
27. Costanza ME, Nathanson L, Schoenfeld D, et al. Results with methyl-CCNU and DTIC in metastatic melanoma. Cancer. 1997;40:1010-1015
28. Avril MF, Bonneterre J, Delaunay M, et al. Combination chemotherapy of dacarbazine and fotemustine in disseminated malignant melanoma. Experience of the French Study Group. Cancer Chemother Pharmacol. 1990;27: 81-84.
29. Costanzi JJ, Vaitkevicius VK, Quagliana JM, et al. Combination chemotherapy for disseminated malignant melanoma. Cancer. 1975;35:342-346.
30. Fletcher WS, Green S, Fletcher JR, et al. Evaluation of cis-platinum and DTIC combination chemotherapy in disseminated melanoma. A Southwest Oncology Group Study. Am J Clin Oncol. 1988;11:589-593.
31. Vorobiof DA, Sarli R, Falkson G. Combination chemotherapy with dacarbazine and vindesine in the treatment of metastatic malignant melanoma.Cancer Treat Rep. 1986;70:927-928. (Pubitemid 16058569)
32. del Prete SA, Maurer LH, O'Donnell J. Combination chemotherapy with cisplatin, carmustine, dacarbazine and tamoxifen in metastatic melanoma.Cancer Treat Rep. 1984;68:1403-1405. (Pubitemid 15222028)
33. Lattanzi SC, Tosteson T, Chertoff J, et al. Dacarbazine, cisplatin and carmustine, with or without tamoxifen, for metastatic melanoma: 5-year followup. Melanoma Res. 1995;5:365-369.
34. Rusthoven JJ, Quirt IC, Iscoe NA, et al. Randomized, double-blind placebocontrolled trial comparing the response rates of carmustine, dacarbazine and cisplatin with and without tamoxifen in patients with metastatic melanoma. J Clin Oncol. 1996;14:2083-2090. (Pubitemid 26230110)
35. Chapman PB, Einhorn LH, Meyers ML, et al. Phase III multicenter randomized trial of Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol. 1999;17:2745-2751. (Pubitemid 29415231)
36. Legha SS, Ring S, Papadopoulos N, et al. A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine and dacarbazine (CVD) for metastatic melanoma. Cancer. 1989;64:2024-2029. (Pubitemid 19280399)
37. Buzaid AC, Legha S, Winn R, et al. Cisplatin (C), Vinblastine (V), and Dacarbazine (D) (CVD) versus dacarbazine alone in metastatic melanoma: preliminary results of a Phase II Cancer Community Oncology Program (CCOP) trial [abstract]. Proc Am Soc Clin Oncol. 1993;12:389a.
38. Hodi FS, Soiffer RJ, Clark J, et al. Phase II study of paclitaxel and carboplatin for malignant melanoma. Am J Clin Oncol. 2002;25:283-286. (Pubitemid 34602552)
39. Zimpfer-Rechner C, Hofmann U, Figl R, et al. Randomized phase II study of weekly paclitaxel versus paclitaxel and carboplatin as second-line therapy in disseminated melanoma: a multicentre trial of the Dermatologic Co-operative Oncology Group (DeCOG). Melanoma Res. 2003;13:531-536. (Pubitemid 37266956)
40. Rao RD, Holtan SG, Ingle JN, et al. Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma. Cancer. 2006;106:375-382. (Pubitemid 43100447)
41. Cocconi G, Bella M, Calabresi F, et al. Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. N Engl J Med. 1992;327:516-523.
42. Falkson CI, Falkson G, Falkson HC. Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma. J Clin Oncol. 1991;9:1403-1408.
43. Lens MB, Reiman T, Husain AF. Use of tamoxifen in the treatment of malignant melanoma. Systematic review and meta-analysis of randomized controlled trial. Cancer. 2003;98:1355-1361. (Pubitemid 37151488)
44. Hwu WJ, Krown SE, Menell JH, et al. Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J Clin Oncol. 2003; 21:3351-3356. (Pubitemid 46606269)
45. Danson S, Lorigan P, Arance A, et al. Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. J Clin Oncol. 2003;21:2551-2557. (Pubitemid 46606337)
46. Hwu WJ, Lis E, Menell JH, et al. Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study. Cancer. 2005;103:2590-2597. (Pubitemid 40800539)
47. Atkins MB, Sosman J, Agarwala S, et al. A Cytokine Working Group phase II study of temozolomide (TMZ), thalidomide (THAL) and whole brain radiation therapy (WBRT) for patients with brain metastases from melanoma (2005 ASCO Annual Meeting Proceedings). J Clin Oncol. 2005;23(suppl):16S. Abstract 7552.
48. Flaherty LE, Robinson W, Redman BG, et al. A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin-2 in metastatic malignant melanoma. Cancer. 1993;71:3520-3525. (Pubitemid 23152659)
49. Atkins MB, O'Boyle KR, Sosma JA, et al. Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma. J Clin Oncol. 1994;12:1553-1560. (Pubitemid 24244989)
50. Legha SS, Ring S, Eton O, et al. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol. 1998;16:1752-1759. (Pubitemid 28234719)
51. O'Day SJ, Gammon G, Boasberg PD, et al. Advantages of concurrent biochemotherapy modifled by decrescendo interleukin-2, granulocyte colony-stimulating factor and tamoxifen for patients with metastatic melanoma. J Clin Oncol. 1999;17:2752-2761. (Pubitemid 29415232)
52. Keilholz U, Conradt C, Legha SS, et al. Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. J Clin Oncol. 1998;16:2921-2929. (Pubitemid 28417410)
53. Keilholz U, Punt CJ, Gore M, et al. Dacarbazine, cisplatin and interferonalfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organization for Research and Treatment of Cancer Melanoma Group. J Clin Oncol. 2005;23:6747-6755. (Pubitemid 46190270)
54. Keilholz U, Goey SH, Punt CJ, et al. Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. J Clin Oncol. 1997;15:2579-2588. (Pubitemid 27289888)
55. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol. 1999;17:968-975. (Pubitemid 29109330)
56. Atkins MB, Lee S, Flaherty LE, et al. A prospective randomized phase III trial of concurrent biochemotherapy (BCT) with cisplatin, vinblastine, dacarbazine (CVD), IL-2 and interferon alpha-2b (IFN) versus CVD alone in patients with metastatic melanoma (E3695): an ECOG-coordinated intergroup trial. Proc Am Soc Clin Oncol. 2003;22:708. Abstract 2847.
57. Eton O, Legha SS, Bedikian AY, et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol. 2002;20:2045-2052. (Pubitemid 34408794)
58. Atkins MB, Hsu J, Lee S, et al. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2008;26:5748-5754.
59. Sato T, Eschelman DJ, Gonsalves CF, et al. Immunoembolization of malignant liver tumors, including uveal melanoma, using granulocyte-macrophage colony-stimulating factor. J Clin Oncol. 2008;26:5436-4542.
60. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099-7109. (Pubitemid 39331023)
61. Karasarides M, Chiloeches A, Hayward R, et al. B-RAF is a therapeutic target in melanoma. Oncogene. 2004;23:6292-6298. (Pubitemid 39215299)
62. Strumberg D, Richly H, Hilger RA, et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol. 2005;23:965-972. (Pubitemid 46202316)
63. Ahmad T, Marais R, Pyle L, et al. BAY 43-9006 in patients with advanced melanoma: the Royal Marsden experience. 2004 ASCO Annual Meeting Proceedings (Post-meeting Edition). J Clin Oncol. 2004;22(suppl):14S. Abstract 7506.
64. Eisen T, Ahmad T, Flaherty KT, et al. Sorafenib in advanced melanoma: a phase II randomized discontinuation trial analysis. Br J Cancer. 2006;95:581-586. (Pubitemid 44325897)
65. Flaherty KT, Brose M, Schucter L, et al. Phase I/II trial of BAY 43-9006, carboplatin (C) and paclitaxel (P) demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma. 2004 ASCO Annual Meeting Proceedings (Post-meeting Edition). J Clin Oncol. 2004; 22(suppl):14S. Abstract 7507.
66. Amaravadi R, Schucter LM, Kramer A, et al. Preliminary results of a randomized phase II study comparing two schedules of temozolomide in combination with sorafenib in patients with advanced melanoma. 2005 ASCO Annual Meeting Proceedings. J Clin Oncol. 2006;24(suppl):18S. Abstract 8009.
67. Berkenblit A, Eder JP Jr, Ryan DP, et al. Phase I clinical trial of STA-4783 in combination with paclitaxel in patients with refractory solid tumors. Clin Cancer Res. 2007;13(2 pt 1):584-590. (Pubitemid 46225365)
68. O'Day S, Gonzalez R, Lawson D, et al; 4783 Melanoma Study Group l. Subgroup analysis of efflcacy and safety analysis of a randomized, doubleblinded controlled phase II study of STA-4783 in combination with paclitaxel in patients with metastatic melanoma [abstract]. J Clin Oncol. 2007;25:479s.
69. Wyman K, Atkins MB, Prieto V, et al. Multicenter phase II trial of high-dose imatinib mesylate in metastatic melanoma: signiflcant toxicity with no clinical efflcacy. Cancer. 2006;106:2005-2011. (Pubitemid 43673217)
70. Tchekmedyian S, Glasby J, Korman A, et al. MDX-010 (human anti-CTLA4): a phase I trial in malignant melanoma-abstract-. Proc Am Soc Clin Oncol. 2002;21:Abstract 56.
71. Ribas A, Camacho LH, Lopez-Berestein G, et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol. 2005;23:8968-8977. (Pubitemid 46217464)
72. Hersh EM, Weber JJ, Powderly J, et al. A phase II, randomized multi-center study of MDX-010 alone or in combination with dacarbazine (DTIC) in stage IV metastatic malignant melanoma. 2004 ASCO Annual Meeting Proceedings (Post-meeting Edition). J Clin Oncol. 2004;22(suppl):14S. Abstract 7511.
73. Fischkoff SA, Hersh E, Weber J, et al. Durable responses and long-term progression-free survival observed in a phase II study of MDX-010 alone or in combination with dacarbazine (DTIC) in metastatic melanoma. Proc Am Soc Clin Oncol. 2005;23:716S. Abstract 7525.
74. Weber JS, Hersh EM, Yellin M, et al. The efflcacy and safety of ipilimumab (MDX-010) in patients with unresectable stage III or stage IV malignant melanoma. ASCO Annual Meeting Proceedings Part I. J Clin Oncol. 2007;25(18S):Abstract 8523.
75. Maio M, Hoos A, Ibrahim R, et al. Efficacy and safety of ipilimumab in patients with advanced melanoma who had progressed on one or more prior therapies: results from a single-arm, multicenter study. Poster presented at: European Society for Medical Oncology; Stockholm, Sweden; September 15, 2008. Poster no. 776PD (Study 008).
76. Lebbe C, Hoos A, Chin K, et al. Effect of dose on efflcacy and safety in ipilimumab-treated patients with advanced melanoma: results from a phase II, randomized, dose-ranging study. Paper presented at: European Society for Medical Oncology; Stockholm, Sweden; September 15, 2008. Oral Presentation No. 769O (Study 022).
77. Ridolfl R, Berman D, Siegel J, et al. Efflcacy and safety of treatment naïve and previously treated patients with advanced melanoma receiving ipilimumab. Poster presented at: European Society for Medical Oncology; Stockholm, Sweden; September 15, 2008. Poster no. 778PD (Study 007).
78. Ribas A, Hauschild A, Kefford R, et al. Phase III, open label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (TMZ or DTIC) in patients with advanced melanoma. J Clin Oncol. 2008;26(suppl): Abstract LBA9011.
79. Blansfleld JA, Beck KE, Tran K, et al. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother. 2005;28:593-598. (Pubitemid 41533093)
80. Bedikian AY, Millward M, Pehamberger H, et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol. 2006;24:4738-4745. (Pubitemid 46630937)
81. Eggermont AM. Reaching flrst base in the treatment of metastatic melanoma [editorial]. J Clin Oncol. 2006;24:4673-4674. (Pubitemid 46630929)
82. Mitjans F, Meyer T, Fittschen C, et al. In vivo therapy of malignant melanoma by means of antagonists of aV integrins. Int J Cancer. 2000;87:716-723. (Pubitemid 30620415)
83. Hersey P, Sosman J, O'Day S, et al. A phase II, randomized, open-label study evaluating the antitumor activity of MEDI-522, a humanized monoclonal antibody directed against the human metastatic melanoma (MM). J Clin Oncol. 2005;23:711S. sAbstract 7507.
84. Jaissle GB, Ulmer A, Henke-Fahle S, et al. Suppression of melanomaassociated neoangiogenesis by bevacizumab. Arch Dermatol. 2008;144: 525-527.
85. Perez DG, Suman V, Amatruda T, et al. Phase II trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma. ASCO Annual Meeting Proceedings Part I. J Clin Oncol. 2007; 25(suppl):Abstract 8560.
86. Fruehauf JP, Lutzky J, McDermott CK, et al. Axitinib (AG-013736) in patients with metastatic melanoma: a phase II study. J Clin Oncol. 2008; 26(suppl):Abstract 9006.
87. Rao RD, Windschitl HE, Allred JB, et al. Phase II trial of the mTOR inhibitor everolimus (RAD-001) in metastatic melanoma. ASCO Annual Meeting Proceedings Part I. J Clin Oncol. 2006;24(suppl):Abstract 8043.
88. Peyton JD, Spigel DR, Burris HA, et al. Phase II trial of bevacizumab and everolimus in the treatment of patients with metastatic melanoma: preliminary results. J Clin Oncol. 2009;27(suppl):Abstract 9027.
89. Rosenberg SA, Dudley ME. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Natl Acad SciUSA. 2004;101(suppl 2):14639-14645. (Pubitemid 39346736)
90. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314:126-129. (Pubitemid 44547756)
91. Dudley ME, Yang JC, Sherry R, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008;26:5233-5339.
92. Miller AJ, Mihm MC Jr. Melanoma. N Engl J Med. 2006;355:51-65.
93. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949-954. (Pubitemid 34716871)
94. Solit DB, Garraway LA, Pratilas CA, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature. 2006;439:358-362. (Pubitemid 43128863)
95. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353:2135-2147. (Pubitemid 41653105)
96. Curtin JA, Busam K, Pinkel D, et al. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol. 2006;24:4340-4346. (Pubitemid 46630793)